Biomarin Pharmaceutical (BSP:B1MR34) Current Accrued Expense : R$38 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Current Accrued Expense?

Biomarin Pharmaceutical's Current Accrued Expense for the quarter that ended in Mar. 2024 was R$38 Mil.

Biomarin Pharmaceutical's quarterly Current Accrued Expense declined from Sep. 2023 (R$229 Mil) to Dec. 2023 (R$30 Mil) but then increased from Dec. 2023 (R$30 Mil) to Mar. 2024 (R$38 Mil).

Biomarin Pharmaceutical's annual Current Accrued Expense increased from Dec. 2021 (R$34 Mil) to Dec. 2022 (R$43 Mil) but then declined from Dec. 2022 (R$43 Mil) to Dec. 2023 (R$30 Mil).

Biomarin Pharmaceutical Current Accrued Expense Historical Data

The historical data trend for Biomarin Pharmaceutical's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Current Accrued Expense Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

14.11

23.09

34.17

43.47

30.33

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															254.85	231.46	229.26	30.33	37.68

Biomarin Pharmaceutical Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Biomarin Pharmaceutical Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines